

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this document, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this document.



維奧醫藥控股有限公司
Vital Pharmaceutical Holdings Limited

(Incorporated in Cayman Islands with limited liability)
(Stock code: 1164)

PROFIT WARNING

This announcement is made by the Company pursuant to Rule 13.09(1) of the Listing Rules.

The Board announces that the results of the Group for the six months ended 30 June 2009 are expected to record a substantial decrease in profits when compared to the corresponding period in 2008. Such decrements are mainly attributable to the impairment losses recognized in respect of goodwill.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

The announcement is made by Vital Pharmaceutical Holdings Limited (the “**Company**”, together with its subsidiaries as the “**Group**”) pursuant to Rule 13.09(1) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The Board announces that the results of the Group for the six months ended 30 June 2009 are expected to record a substantial decrease in profits when compared to the corresponding period in 2008. Such decrements are mainly attributable to the impairment losses recognized in respect of goodwill.

The Company is in the process of preparing the interim results of the Group for the six months ended 30 June 2009. The information contained in this announcement is only based on the information currently available to the Company, a valuation report issued by BMI Appraisals Limited which was received by the Company on 18 September 2009, and is not based on any figures or information that has been audited or reviewed by the Company’s auditors. Details of the Group’s performance will be disclosed as and when the final interim results for the six months ended 30 June 2009 are announced.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

The Board as at the date of this announcement comprises six executive directors: Mr. Tao Lung, Mr. Huang Jianming, Mr. Xu Xiaofan, Mr. Shen Songqing, Mr. Liu James Jin, and Madam Guo Lin; and three independent non-executive directors: Mr. Lui Tin Nang, Mr. Lee Kwong Yiu and Mr. Chong Cha Hwa.

By Order of the Board
Vital Pharmaceutical Holdings Limited
Tao Lung
Chairman

Hong Kong, 18 September 2009